Cargando…
Baseline history of patients using selexipag for pulmonary arterial hypertension
INTRODUCTION: Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary a...
Autores principales: | Highland, Kristin B., Hull, Michael, Pruett, Janis, Elliott, Caitlin, Tsang, Yuen, Drake, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466463/ https://www.ncbi.nlm.nih.gov/pubmed/30983530 http://dx.doi.org/10.1177/1753466619843774 |
Ejemplares similares
-
Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension
por: Studer, Sean, et al.
Publicado: (2019) -
Selexipag for pulmonary arterial hypertension
Publicado: (2021) -
Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database
por: Studer, Sean, et al.
Publicado: (2018) -
Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019) -
Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
por: Tsang, Yuen, et al.
Publicado: (2023)